Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -48.77%

Predilife S.A. Return on Capital Employed (ROCE) is -48.77% for the year ending December 31, 2023, a -125.30% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Predilife S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 192.73%, a 296.32% change year over year.
Predilife S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -98.17%, a -44.72% change year over year.
Predilife S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -67.84%, a 71.18% change year over year.
Predilife S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -235.38%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years